Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2016

Planlagt Fastgjort Låst Flyttet Genmab
2.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • O Offline
    O Offline
    OHW
    wrote on sidst redigeret af
    #1101

    The combination of D and Rd potentially represents a new standard of care for pts with >1 prior treatment. :-))

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gentogen
      wrote on sidst redigeret af
      #1102

      doubling stringent CR/CR rates

      1 Reply Last reply
      0
      • O Offline
        O Offline
        OHW
        wrote on sidst redigeret af
        #1103

        Man tør næsten ikke drømme om potentialet..

        1 Reply Last reply
        0
        • FantomasF Offline
          FantomasF Offline
          Fantomas
          wrote on sidst redigeret af
          #1104

          Dara kommer til at sende hematology læger på pension..

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #1105

            Heftige data - nogen der har Elotuzumab data ved hånden ?

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #1106

              OFC is a rapidly acting combination, inducing high response rates, including deep and durable responses in heavily pretreated WM patients, even in those refractory to rituximab and/or bortezomib. Ofatumumab is well tolerated

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #1107

                Elo: The co-primary endpoints of this study, progression-free survival (PFS) as assessed by hazard ratio (HR) and overall response rate (ORR), were achieved, with extended follow-up data showing a 53% relative improvement in PFS rate at three years (23% versus 15%). Additionally, a pre-specified interim analysis for overall survival (OS) found a positive trend favoring the Empliciti combination versus Rd alone (HR=0.77 [95% CI: 0.61, 0.97, p=0.0257])

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #1108

                  Among the patients treated with Empliciti, Revlimid, and dex­a­meth­a­sone, 79 percent achieved at least a partial response to treatment, compared to 66 percent of the patients who received Revlimid and dex­a­meth­a­sone alone

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #1109

                    Mere elo: he ERd regimen demonstrated a significant improvement in ORR of 78.5% (95% CI: 73.6-82.9; p=0.0002) versus 65.5% in the Rd arm (95% CI: 60.1-70.7).

                    1 Reply Last reply
                    0
                    • investor1989I Offline
                      investor1989I Offline
                      investor1989
                      wrote on sidst redigeret af
                      #1110

                      with 19% of pts with ≥3 prior lines of therapy

                      1 Reply Last reply
                      0
                      • investor1989I Offline
                        investor1989I Offline
                        investor1989
                        wrote on sidst redigeret af
                        #1111

                        så der var også nogle syge patienter med i studiet

                        1 Reply Last reply
                        0
                        • investor1989I Offline
                          investor1989I Offline
                          investor1989
                          wrote on sidst redigeret af
                          #1112

                          Elo 78 % ORR. Dara 93 % og så en sindssyg 43 % CR oveni. Elo kan godt gå hjem nu

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #1113

                            Altså Elo+Rd 78,5% ORR. Dara+R+d 93%
                            ORR

                            1 Reply Last reply
                            0
                            • investor1989I Offline
                              investor1989I Offline
                              investor1989
                              wrote on sidst redigeret af
                              #1114

                              VGPR var hele 76 % !!! med Dara mod kun 44% i kontrolarmen

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #1115

                                Just a moment...

                                favicon

                                (www.nejm.org)

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  MUFC_Oberanven
                                  wrote on sidst redigeret af
                                  #1116

                                  Kursen er nu 1094

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #1117

                                    Ja, nyheden er nået frem til markedet

                                    1 Reply Last reply
                                    0
                                    • investor1989I Offline
                                      investor1989I Offline
                                      investor1989
                                      wrote on sidst redigeret af
                                      #1118

                                      Prøv lige at tjekke PFS grafen for Dara. 80 % af patienter er stadig med efter 12 måneder !! Efter 21 måneder er de stadig omkring 75. Der går lang tid endnu før de rammer 50 og dermed finder median PFS..

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #1119

                                        man skal nok passe på at sammenligne alt for meget, men Dara ser godt nok stærk ud 🙂

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #1120

                                          Ja Daras styrke er jo de lange dybe responser 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger